Bromfenac (DB00963): A Comprehensive Pharmacological and Clinical Monograph

1.0 Executive Summary

Bromfenac is a potent, small-molecule nonsteroidal anti-inflammatory drug (NSAID) belonging to the phenylacetic acid class, identified by DrugBank ID DB00963.[1] It is administered topically as an ophthalmic solution, with its primary clinical indication being the treatment of postoperative inflammation and the reduction of ocular pain in patients who have undergone cataract surgery.[3] The drug exerts its therapeutic effect through the potent inhibition of cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2, thereby blocking the synthesis of prostaglandins that mediate inflammation and pain.[6] Pharmacologically, Bromfenac is distinguished by a notable preference for inhibiting the COX-2 isoenzyme, which is primarily induced during inflammatory processes.[1]

A key feature of Bromfenac is its unique chemical structure, which includes a bromine atom. This halogenation significantly enhances the molecule's lipophilicity, leading to superior penetration into ocular tissues and a higher intrinsic potency compared to other ophthalmic NSAIDs.[8] This pharmacokinetic advantage allows for high, sustained therapeutic concentrations within the aqueous humor for at least 12 hours, facilitating convenient once or twice-daily dosing regimens that can improve patient adherence.[1] The ophthalmic formulation has a well-established safety profile, with the most common adverse effects being localized and transient, such as stinging upon instillation and eye redness.[4] However, a significant, albeit rare, risk involves corneal complications, necessitating careful patient monitoring.[14]

The history of Bromfenac is marked by a critical distinction between its ophthalmic and oral formulations. An oral version, Duract®, was withdrawn from the market in 1998 due to severe, idiosyncratic hepatotoxicity observed with prolonged use.[2] The successful redevelopment of Bromfenac as a topical agent is predicated on its pharmacokinetic profile; negligible systemic absorption from ocular administration effectively isolates the body from the risks that doomed the oral form.[1] This monograph provides a comprehensive analysis of Bromfenac's chemistry, pharmacology, clinical use, safety, and regulatory history, positioning it as a cornerstone therapy in postoperative ophthalmic care.

2.0 Drug Identity and Physicochemical Properties

2.1 Nomenclature and Identifiers

The precise identification of a pharmaceutical agent is fundamental to its scientific and clinical understanding. Bromfenac is classified as a small molecule drug.[7] Its formal chemical and regulatory identifiers are cataloged across multiple international databases.

• Generic Name: Bromfenac.[3]
• IUPAC Name: 2-[2-amino-3-(4-bromobenzoyl)phenyl]acetic acid.[1]
• CAS Number: The Chemical Abstracts Service (CAS) registry number for the free acid form is 91714-94-2.[1] The commonly used salt forms have distinct identifiers: 91714-93-1 for the sodium salt and 120638-55-3 for the sodium salt sesquihydrate.[1]
• Database Identifiers: Key database accession numbers include DrugBank ID DB00963, PubChem CID 60726, ChemSpider 54730, FDA UNII 864P0921DW, and KEGG D07541.[1]
• ATC Code: The Anatomical Therapeutic Chemical (ATC) classification system code for Bromfenac is S01BC11.[19]
• Synonyms: The compound is known by various synonyms reflecting its global development and marketing, including Bromfenaco, Bromfenacum, AHR 10282, Yellox, and the discontinued brand name Xibrom.[2]

2.2 Chemical Structure and Formulation Analysis

Bromfenac's chemical structure is central to its pharmacological activity. Its empirical formula is C15​H12​BrNO3​, with a molecular weight of approximately 334.16 g/mol.[2]

Chemically, Bromfenac is a member of the benzophenone, substituted aniline, and organobromine compound families.[2] It is classified within the acetic acid group of NSAIDs, which also includes prominent drugs like diclofenac and indomethacin.[1] Bromfenac is functionally and structurally related to amfenac; it is essentially amfenac with a bromine atom substituted for a hydrogen atom at the C4 position of the benzoyl ring.[2] This single halogenation has profound effects on its potency and pharmacokinetic properties.

For clinical use in ophthalmic solutions, Bromfenac is formulated as its sodium salt, specifically bromfenac sodium sesquihydrate (C15​H11​BrNNaO3​⋅1.5H2​O), which has a molecular weight of 383.17.[4] The selection of this salt form is a deliberate pharmaceutical strategy. The core Bromfenac molecule is highly lipophilic, a property essential for penetrating the lipid-rich corneal epithelium but which makes it poorly soluble in water.[10] Converting it to the sodium salt form renders it water-soluble, allowing for its formulation as a stable aqueous eye drop.[1] The sesquihydrate form is chosen to optimize the crystalline structure for manufacturing stability and consistent dissolution characteristics in the final product. This represents a classic pharmaceutical solution to the challenge of balancing solubility in the container with the lipophilicity required to cross biological barriers at the site of action.

2.3 Physicochemical Characteristics and Formulation Details

Bromfenac sodium appears as a yellow to orange crystalline powder.[4] It is soluble in water, methanol, and aqueous bases, but insoluble in chloroform and aqueous acids.[1]

Ophthalmic formulations are sterile aqueous solutions containing a variety of excipients to ensure stability, sterility, and tolerability. These inactive ingredients typically include:

• Buffering agents: Boric acid and sodium borate to maintain the solution at an alkaline pH, typically between 7.8 and 8.3.[4]
• Preservative: Benzalkonium chloride (0.005%) to prevent microbial contamination.[4]
• Antioxidant: Sodium sulfite to protect the active ingredient from oxidative degradation.[4] The inclusion of this excipient carries a specific warning, as sulfites can cause allergic reactions in susceptible individuals, particularly those with asthma.[3]
• Other excipients: These may include chelating agents like edetate disodium, viscosity enhancers like povidone, and surfactants like polysorbate 80 or tyloxapol to improve solubility and stability.[4]

A notable formulation innovation is the use of the DuraSite® mucoadhesive matrix in the BromSite® brand. This delivery system is a polymer-based formulation designed to increase the residence time of the drug on the ocular surface, thereby enhancing its penetration and bioavailability.[14]

Table 2.1: Bromfenac Identifiers and Chemical Properties

Property	Value	Source(s)
IUPAC Name	2-[2-amino-3-(4-bromobenzoyl)phenyl]acetic acid	1
CAS Number (Free Acid)	91714-94-2	1
CAS Number (Sodium Salt)	91714-93-1	21
CAS Number (Sodium Sesquihydrate)	120638-55-3	1
DrugBank ID	DB00963	1
Chemical Formula (Free Acid)	C15​H12​BrNO3​	2
Molecular Weight (Free Acid)	334.16 g/mol	2
Physical Appearance (Sodium Salt)	Yellow to orange crystalline powder	4
Solubility (Sodium Salt)	Soluble in water, methanol, aqueous bases	1
pKa (Predicted)	4.07	22
ATC Code	S01BC11	19

3.0 Pharmacology

3.1 Mechanism of Action: Cyclooxygenase Inhibition

Bromfenac is a classic nonsteroidal anti-inflammatory drug (NSAID) whose therapeutic effects are derived from its ability to modulate the arachidonic acid cascade.[2] The core mechanism of action is the inhibition of prostaglandin synthesis.[6] This is achieved by blocking the activity of the cyclooxygenase (COX) enzymes, which are responsible for converting arachidonic acid into prostaglandin precursors.[2] Bromfenac has been shown to inhibit both major isoforms of the enzyme, COX-1 and COX-2.[6]

A defining pharmacological characteristic of Bromfenac is its preferential inhibition of COX-2 over COX-1.[1] This selectivity is clinically relevant because the COX-1 isoform is constitutively expressed and involved in homeostatic physiological functions, such as maintaining the protective gastric mucosal lining, while the COX-2 isoform is primarily induced at sites of injury and inflammation.[30] For systemically administered NSAIDs, COX-2 selectivity is highly valued as it can reduce the risk of gastrointestinal side effects. While this benefit is less critical for a topical ophthalmic agent with negligible systemic absorption, the potent targeting of COX-2—the key enzyme upregulated in ocular inflammation—is central to Bromfenac's powerful local anti-inflammatory effect.

The high potency of Bromfenac is substantiated by quantitative in vitro data. Its 50% inhibitory concentrations (IC50) for recombinant human COX-1 and COX-2 have been reported to be 5.56 nM and 7.45 nM, respectively.[21] Comparative studies consistently demonstrate that Bromfenac is a more potent inhibitor of COX-2 than other commonly used ophthalmic NSAIDs, including diclofenac and amfenac (the active metabolite of nepafenac).[9]

Table 3.1: Comparative COX Inhibition (IC50 Values)

NSAID	COX-1 IC50 (nM)	COX-2 IC50 (nM)	Source(s)
Bromfenac	5.56	7.45	21
Ketorolac	13.9	91.1	27
Diclofenac	55.5	30.7	27
Amfenac	15.3	20.4	27
Nepafenac (Prodrug)	82,300	>1,000,000	27

3.2 Pharmacodynamics: Ocular Anti-inflammatory and Analgesic Effects

In the eye, prostaglandins (PGs) are critical mediators of the inflammatory response to surgical trauma. They have been shown to produce a cascade of effects including the disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis (an influx of inflammatory cells), and elevation of intraocular pressure.[15] PGs are also primarily responsible for surgically induced miosis, the progressive constriction of the pupil during surgery, which can complicate the procedure.[8]

By potently inhibiting PG synthesis, Bromfenac directly counteracts these effects. This leads to the clinically observed reduction in postoperative inflammation (e.g., anterior chamber cell and flare), swelling, and redness, as well as the alleviation of ocular pain.[9] Furthermore, its ability to inhibit intraoperative miosis is an important pharmacodynamic benefit, helping to maintain a stable and dilated pupil throughout the surgical procedure, an effect comparable to that of other topical NSAIDs.[8]

The clinical utility of Bromfenac is a direct result of a synergistic relationship between its chemical structure, pharmacokinetics, and pharmacodynamics. The addition of a bromine atom to the amfenac backbone does more than just create a new molecule; it initiates a positive feedback loop of efficacy. First, the halogenation increases the molecule's lipophilicity, which enhances its ability to penetrate the cornea and other ocular tissues.[8] Second, this same structural change directly increases the drug's intrinsic potency for inhibiting the target COX-2 enzyme.[1] This combination of enhanced delivery (a pharmacokinetic advantage) and increased potency (a pharmacodynamic advantage) means that more of a more powerful drug reaches the site of inflammation. This synergy explains how Bromfenac can achieve high, sustained therapeutic concentrations in the aqueous humor for over 12 hours from a single drop, enabling the convenient once or twice-daily dosing regimens that distinguish it in the clinical setting.[1]

4.0 Pharmacokinetics

4.1 Ocular Absorption and Distribution

Following topical instillation, Bromfenac is well absorbed through the cornea into the anterior segment of the eye.[1] This efficient absorption is facilitated by the molecule's brominated structure, which confers a high degree of lipophilicity, allowing it to readily cross the lipid-rich corneal epithelium.[8]

Clinical pharmacokinetic studies in humans have shown that Bromfenac reaches its maximum concentration (Cmax) in the aqueous humor approximately 150 to 180 minutes (2.5 to 3 hours) after administration of a single drop.[1] The drug distributes primarily to the tissues of the anterior segment, with the highest concentrations found in the aqueous humor and conjunctiva. Significant levels are also detected in the iris-ciliary body, sclera, choroid, and retina, while much lower concentrations are found in the lens and vitreous body.[1] This distribution pattern ensures the drug is concentrated at the primary sites of inflammation following cataract surgery. Formulations utilizing advanced delivery systems, such as BromSite® with its DuraSite® vehicle, have been shown to yield significantly higher and more sustained drug concentrations in ocular tissues compared to conventional solutions.[29]

The duration of action is a key clinical feature. High drug levels are maintained in the aqueous humor for at least 12 hours post-instillation. Pharmacokinetic modeling confirms that concentrations remain above the IC50 for COX-2 throughout this period, providing the scientific rationale for the efficacy of once-daily and twice-daily dosing regimens.[1]

4.2 Systemic Exposure, Metabolism, and Excretion

A critical aspect of Bromfenac's pharmacokinetic profile, and the cornerstone of its safety, is its negligible systemic exposure following topical ocular administration. Multiple studies have confirmed that plasma concentrations of Bromfenac in humans after ophthalmic use are below the lower limit of quantification, which is typically 50 ng/mL.[1] This minimal systemic absorption effectively isolates the rest of the body, particularly the liver, from clinically significant drug exposure. This pharmacokinetic reality is what allows for the safe use of ophthalmic Bromfenac, in stark contrast to the severe hepatotoxicity that led to the withdrawal of its oral formulation, Duract®.[2]

In the unlikely event of systemic absorption, Bromfenac is known to be highly bound (99.8%) to plasma proteins, primarily albumin.[1] The drug is metabolized principally by the hepatic enzyme Cytochrome P450 2C9 (CYP2C9).[1] The metabolic process yields several compounds, including a major active metabolite, a cyclic amide known as bromfenac lactam, as well as other conjugated metabolites.[1]

The elimination half-life of Bromfenac in the aqueous humor is approximately 1.4 hours.[1] After oral administration, the systemic half-life was reported to be between 0.5 and 4.0 hours, indicating rapid elimination.[25] Following metabolism, the drug and its metabolites are cleared from the body primarily via the kidneys. Studies on the disposition of the drug show that approximately 82% of a dose is excreted in the urine, with an additional 13% eliminated in the faeces.[1]

The evolution of Bromfenac formulations demonstrates a sophisticated approach to optimizing drug delivery. While the initial formulations like Xibrom® were effective, the development of products like BromSite® with the DuraSite® vehicle represents a strategic shift. This innovation focuses not on altering the active molecule but on enhancing the delivery system. By increasing the drug's residence time on the ocular surface, the mucoadhesive DuraSite® matrix improves the pharmacokinetic profile, leading to higher and more sustained drug concentrations in target tissues.[29] This illustrates a key principle in modern pharmaceutical development: once a potent molecule is identified, the next frontier of innovation often lies in optimizing its delivery to maximize efficacy and patient convenience.

5.0 Clinical Efficacy and Therapeutic Use

5.1 Approved Indications and Clinical Utility

The primary, FDA-approved indication for bromfenac ophthalmic solution is for the treatment of postoperative inflammation and the reduction of ocular pain in patients who have undergone cataract surgery.[2] This indication is consistent across its various formulations and concentrations. Some formulations carry slightly nuanced labeling; for instance, BromSite® (bromfenac 0.075%) is specifically indicated for the

prevention of ocular pain in addition to the treatment of postoperative inflammation.[14]

The therapeutic scope of Bromfenac is broader in some international markets. In Japan, where the drug was first approved as Bronuck®, its indications extend to the treatment of other external and anterior ocular inflammatory diseases, such as blepharitis, conjunctivitis, and scleritis.[9]

5.2 Dosing, Administration, and Commercial Formulations

The dosing regimen for ophthalmic Bromfenac has evolved, leading to several commercially available products with distinct schedules. This has been a key part of the drug's lifecycle management, aiming to improve patient adherence and differentiate products in the marketplace.

Table 5.1: Summary of Commercial Formulations and Dosing Regimens

Brand Name(s)	Concentration	Dosing Frequency	Typical Dosing Schedule	Key Indication
Prolensa®, Bromday® (discontinued)	0.07%, 0.09%	Once Daily	1 drop daily, starting 1 day pre-op, day of surgery, and for 14 days post-op	Treatment of postoperative inflammation and reduction of ocular pain 3
BromSite®	0.075%	Twice Daily	1 drop twice daily (morning/evening), starting 1 day pre-op, day of surgery, and for 14 days post-op	Treatment of postoperative inflammation and prevention of ocular pain 3
Xibrom® (discontinued)	0.09%	Twice Daily	1 drop twice daily, starting 24 hours post-op for 14 days	Treatment of postoperative inflammation and reduction of ocular pain 1

Proper administration technique is crucial for efficacy and safety. Patients should be counseled to wash their hands before use, tilt their head back, and instill one drop into the conjunctival sac without allowing the dropper tip to touch the eye or any other surface to avoid contamination. If other ophthalmic medications are being used, patients should wait at least five minutes between instillations. Contact lenses must be removed prior to using Bromfenac and can be reinserted after 10-15 minutes.[3]

5.3 Efficacy in Clinical Trials

The clinical efficacy of Bromfenac is well-supported by numerous large-scale, randomized, double-masked, placebo-controlled trials. These studies have consistently shown that Bromfenac, in both its once-daily and twice-daily formulations, is significantly superior to placebo for its approved indications.[9] The primary efficacy endpoint in these trials is typically the proportion of subjects with complete clearance of anterior chamber inflammation (a summed ocular inflammation score, or SOIS, of 0), and a key secondary endpoint is the proportion of subjects who are pain-free.

For example, in pooled results from two pivotal trials of once-daily bromfenac 0.09%, 73.9% of subjects in the Bromfenac group had cleared inflammation by day 15, compared to only 40.4% in the placebo group (p<0.0001).[9] Similarly, significantly more subjects treated with Bromfenac were pain-free at Day 1 post-surgery compared to those receiving placebo.[41] These robust results established the foundation for its regulatory approvals.

5.4 Off-Label Applications: Management of Cystoid Macular Edema (CME)

Beyond its approved indications, Bromfenac is widely used off-label for the prevention and treatment of cystoid macular edema (CME) following cataract surgery.[1] CME, a condition characterized by fluid accumulation in the macula, is a significant cause of suboptimal visual outcomes after otherwise successful surgery. There is a substantial body of clinical evidence supporting the prophylactic use of topical NSAIDs to reduce the incidence of CME.[9]

Studies and reviews have shown that Bromfenac is effective in this role, demonstrating comparable or superior efficacy to topical corticosteroids in minimizing changes in retinal thickness and macular volume postoperatively.[42] This effect is particularly notable in high-risk populations, such as patients with diabetes.[42] Furthermore, case series suggest that Bromfenac can be an effective second-line therapy for treating established, persistent CME in patients who have not responded to first-line treatment with other NSAIDs like ketorolac, a benefit potentially attributable to Bromfenac's greater potency and superior penetration into the posterior segment of the eye.[44]

This common off-label use highlights a gap that can exist between extensive clinical evidence and formal regulatory indications. While nepafenac has received an indication for CME prevention in the European Union, no topical NSAID, including Bromfenac, holds this specific indication in the United States, despite widespread use for this purpose based on compelling data from the medical literature.[9] This reflects the high bar for evidence required by regulatory agencies and points to a potential area for future clinical trials and label expansion.

6.0 Safety and Tolerability Profile

6.1 Ophthalmic Adverse Events

Ophthalmic Bromfenac is generally well-tolerated, with most adverse reactions being local, transient, and mild to moderate in severity. The safety profile has been characterized through extensive clinical trials and post-marketing surveillance.

Table 6.1: Adverse Events Associated with Ophthalmic Bromfenac

Frequency Category	Adverse Events	Source(s)
Common (2-8% of patients)	Abnormal sensation in eye, foreign body sensation, transient burning/stinging upon instillation, eye irritation, conjunctival hyperemia (redness), eye pain, eye pruritus (itching), photophobia (light sensitivity), transient blurred vision, headache.	3
Less Common (1-8% in some studies)	Anterior chamber inflammation, iritis, vitreous floaters, ocular hypertension.	14
Rare / Post-marketing	Keratitis, corneal erosion, corneal thinning, corneal epithelial breakdown, corneal ulceration, corneal perforation.	1

The most significant safety concern, though rare, is the potential for serious corneal adverse events. These events, which can be sight-threatening, underscore the importance of proper patient selection and monitoring.[1]

6.2 Warnings, Precautions, and Contraindications

The prescribing information for all Bromfenac formulations includes several important warnings and precautions:

• Contraindications: Bromfenac is contraindicated in individuals with a known hypersensitivity to the drug or any of its components, as well as in patients who have experienced asthma, urticaria, or other allergic-type reactions in response to aspirin or other NSAIDs.[1]
• Sulfite Allergic Reactions: Formulations contain sodium sulfite, an antioxidant that may cause severe allergic reactions, including anaphylaxis and life-threatening asthmatic episodes, in certain susceptible people. Sulfite sensitivity is seen more frequently in individuals with asthma.[3]
• Slow or Delayed Healing: As with all topical NSAIDs, Bromfenac may slow or delay the healing process, particularly of the cornea. This effect can be potentiated by the concomitant use of topical corticosteroids.[3]
• Increased Bleeding Time: Bromfenac can interfere with platelet aggregation. While systemic effects are minimal, there is a potential for increased bleeding of ocular tissues (e.g., hyphemas) in conjunction with surgery. Caution is advised for patients with known bleeding tendencies or those taking anticoagulant or antiplatelet medications.[4]
• Corneal Effects: This is the most critical warning. Use of topical NSAIDs can lead to keratitis. In some susceptible patients, continued use may result in epithelial breakdown, corneal thinning, erosion, ulceration, or perforation. The risk is elevated in patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), and rheumatoid arthritis. Post-marketing experience also suggests that using the drug for longer than the recommended 14-day postoperative period may increase the risk and severity of these corneal events.[3]
• Contact Lens Wear: Patients should be instructed not to wear contact lenses while being treated with Bromfenac eye drops. The preservative benzalkonium chloride may be absorbed by soft contact lenses.[4]

6.3 Use in Specific Populations

• Pregnancy: Bromfenac is designated as Pregnancy Category C. Animal reproduction studies at high oral doses revealed embryo-fetal lethality but no structural teratogenicity. Due to the known effects of prostaglandin-inhibiting drugs on the fetal cardiovascular system (premature closure of the ductus arteriosus), the use of Bromfenac during late pregnancy should be avoided. Systemic exposure from topical use is expected to be minimal.[14]
• Lactation: It is not known whether Bromfenac is excreted in human milk. However, given the negligible systemic absorption following ocular administration, the risk to a breastfed infant is considered low. Patients can be advised to use punctal occlusion to further minimize any systemic absorption.[15]
• Pediatrics: The safety and effectiveness of Bromfenac in pediatric patients (below the age of 18) have not been established.[3]
• Geriatrics: Clinical studies have not demonstrated any overall differences in the safety or efficacy of Bromfenac in elderly patients compared to younger adult patients.[3]

6.4 A Critical Historical Note: The Withdrawal of Oral Bromfenac (Duract®) and Hepatotoxicity

The safety profile of ophthalmic Bromfenac cannot be fully appreciated without understanding the history of its oral formulation, Duract®. Developed by Wyeth-Ayerst, Duract® capsules were approved by the FDA in July 1997 for the short-term (10 days or less) management of acute pain.[17]

Less than one year after its launch, Duract® was voluntarily withdrawn from the market on June 22, 1998.[2] The withdrawal was prompted by numerous post-marketing reports of severe, idiosyncratic drug-induced liver injury (DILI). These cases included fulminant hepatic failure, resulting in some patients requiring liver transplantation and four reported deaths.[18] A crucial observation was that these severe events occurred almost exclusively in patients who had taken the drug for periods longer than the 10-day limit specified in the label.[17]

The Duract® episode serves as a powerful case study in pharmacovigilance. The pre-market clinical trials, while showing a signal of elevated liver enzymes with long-term use, did not detect the rare but catastrophic risk of liver failure.[17] This severe adverse event signal only became apparent after the drug was exposed to a large, heterogeneous patient population in the real world. The FDA and Wyeth-Ayerst initially responded by adding a "black box" warning to the label, but continued reports of severe hepatotoxicity led to the conclusion that the 10-day use restriction was impractical to enforce, making market withdrawal the most prudent course of action to protect public health.[17] This history underscores the limitations of pre-market trials for detecting rare idiosyncratic reactions and highlights the indispensable role of post-marketing surveillance.

7.0 Drug-Drug Interactions

The potential for drug-drug interactions with ophthalmic Bromfenac is primarily limited to other concurrently administered topical medications, as systemic absorption is negligible.

• Topical Corticosteroids: The most clinically significant interaction is with topical corticosteroids (e.g., prednisolone, dexamethasone). Both NSAIDs and corticosteroids are known to slow or delay healing. Their concomitant use may potentiate this effect, increasing the risk for corneal healing problems.[3]
• Other Ophthalmic NSAIDs: Co-administration with another topical NSAID (e.g., ketorolac, diclofenac) is not recommended. Such a combination offers no proven benefit and could increase the risk of additive ocular adverse effects.[3]
• Anticoagulants and Antiplatelet Agents: Bromfenac inhibits platelet aggregation. While the risk of systemic bleeding is extremely low, there is a theoretical concern for increased bleeding of ocular tissues (e.g., hyphema) when used with systemic anticoagulants (e.g., warfarin, apixaban) or antiplatelet drugs (e.g., aspirin, clopidogrel). Therefore, caution is recommended when treating patients with known bleeding tendencies or those on these medications.[13]
• Systemic NSAIDs: There is a potential for cross-sensitivity. Patients with a history of hypersensitivity reactions to aspirin or other systemic NSAIDs should use ophthalmic Bromfenac with caution.[15]

While extensive drug interaction databases list numerous potential interactions based on the systemic pharmacology of NSAIDs (e.g., with SSRIs, other NSAIDs), these are of low clinical relevance for the topical ophthalmic route due to the minimal systemic exposure.[1] No systematic interaction studies have been performed with the ophthalmic solution.[1]

Table 7.1: Clinically Significant Drug-Drug Interactions

Interacting Drug Class	Potential Effect	Mechanism	Clinical Management / Recommendation
Topical Corticosteroids	Increased potential for slow or delayed corneal healing.	Additive pharmacodynamic effect; both drug classes can impair wound healing.	Use concomitantly with caution. Monitor corneal health closely, especially in high-risk patients. 14
Other Topical NSAIDs	Increased risk of additive ocular adverse effects.	Additive pharmacodynamic effect on prostaglandin synthesis and potential for increased corneal toxicity.	Concomitant use is not recommended. 3
Systemic Anticoagulants / Antiplatelet Agents	Potential for increased bleeding time of ocular tissues (e.g., hyphema).	Inhibition of platelet aggregation by Bromfenac.	Use with caution, particularly in the perioperative period. Monitor for signs of ocular bleeding. 13
Systemic NSAIDs / Aspirin	Potential for cross-sensitivity reactions (e.g., asthma, urticaria).	Immunological cross-reactivity among NSAIDs.	Contraindicated in patients with known hypersensitivity. Use with caution in individuals with a history of NSAID sensitivity. 15

8.0 Comparative Analysis with Other Ophthalmic NSAIDs

The choice of an ophthalmic NSAID for post-cataract care involves a trade-off between efficacy, dosing convenience, safety, and cost. Bromfenac is often compared to other leading agents: ketorolac, nepafenac, and diclofenac.

8.1 Bromfenac vs. Ketorolac

• Efficacy: Multiple studies show that Bromfenac and ketorolac have comparable efficacy in controlling pain and inflammation after refractive and cataract surgery.[56] However, some evidence suggests Bromfenac may be more effective for treating persistent CME, particularly as a second-line agent in cases where ketorolac has failed, which may be due to its different COX selectivity and better posterior segment penetration.[11]
• Dosing and Compliance: A primary advantage of Bromfenac is its less frequent dosing schedule (once or twice daily) compared to the typical four-times-daily regimen for ketorolac. This improved convenience is a significant factor in enhancing patient compliance.[11]
• Indications: Ketorolac has a broader range of approved indications, including the treatment of seasonal allergic conjunctivitis, which is not an indication for Bromfenac.[59]

8.2 Bromfenac vs. Nepafenac

• Pharmacology: The most fundamental difference is that Bromfenac is an active drug molecule, whereas nepafenac is a prodrug that requires enzymatic conversion in ocular tissues to its active form, amfenac.[10] The brominated structure of Bromfenac gives it superior lipophilicity and corneal penetration compared to amfenac.[10] Consequently, Bromfenac is more potent than amfenac at inhibiting both COX-1 and COX-2.[10]
• Efficacy: In studies comparing their ability to maintain mydriasis during cataract surgery, both drugs were found to be highly effective and superior to placebo, with some studies showing a slight clinical edge for Bromfenac, though this was not always statistically significant.[35] One comparative study concluded that Bromfenac was more effective than nepafenac in reducing CME after phacoemulsification.[62]
• Tolerability: Patients have reported significantly more subjective "stickiness" upon instillation of nepafenac compared to Bromfenac, which may affect patient preference.[62]

8.3 Bromfenac vs. Diclofenac

• Potency and Efficacy: Bromfenac is substantially more potent than diclofenac in its inhibition of COX enzymes.[10] In a head-to-head clinical trial, a more intensive and prolonged course of diclofenac (four times daily for 28 days) was found to be more effective at reducing inflammation and macular thickening than a standard course of Bromfenac (twice daily for 14 days).[64]
• Tolerability and Dosing: The same study found that Bromfenac was significantly better tolerated, with a much higher proportion of symptom-free patients. This superior tolerability was attributed to its lower dosing frequency and shorter treatment duration.[64]

8.4 Cost and Dosing Convenience Analysis

• Dosing Convenience: Once or twice-daily dosing gives Bromfenac and some formulations of nepafenac a distinct advantage in patient adherence over older agents like ketorolac and diclofenac, which typically require four-times-daily administration.[11]
• Cost: Cost is a major differentiating factor. The availability of low-cost generics makes ketorolac and diclofenac substantially more affordable than Bromfenac. Representative pricing data indicates that generic ketorolac and diclofenac can cost as little as $3 to $15, whereas generic Bromfenac is significantly more expensive, often in the range of $45 to $70, with branded formulations costing even more.[58]

Table 8.1: Head-to-Head Comparison of Ophthalmic NSAIDs

Feature	Bromfenac	Ketorolac	Nepafenac	Diclofenac
Mechanism	Active Drug	Active Drug	Prodrug (converts to Amfenac)	Active Drug
Primary COX Target	Preferential COX-2 Inhibitor 1	Potent COX-1 Inhibitor 44	Active metabolite (Amfenac) is a COX-1/COX-2 inhibitor 60	COX-1/COX-2 Inhibitor 64
Dosing Frequency	Once or Twice Daily 28	Typically Four Times Daily 11	Once or Three Times Daily 11	Typically Four Times Daily 11
Relative Potency	High; more potent than amfenac and diclofenac 10	Moderate	Moderate (as amfenac)	Lower than Bromfenac 10
Key Efficacy	Potent anti-inflammatory/analgesic; effective in CME 41	Broad indications including allergic conjunctivitis 59	Effective mydriasis maintenance; good posterior penetration 35	Established efficacy, but requires frequent dosing 11
Key Safety/Tolerability	Good tolerability; rare corneal events 15	Generally well-tolerated 59	Reports of "stickiness" upon instillation 62	Less tolerated than Bromfenac in head-to-head study 64
Relative Cost	High (Branded and Generic) 59	Low (Generic) 59	High (Branded) 66	Low (Generic) 66

9.0 Regulatory and Commercial Landscape

9.1 Global Regulatory Status and Approval Timelines

The regulatory journey of Bromfenac is complex, marked by the failure of its oral form and the subsequent successful development and evolution of its ophthalmic formulations worldwide.

• United States (FDA): The history in the U.S. is a multi-stage process:
• Duract® (oral): Approved in 1997 and withdrawn in 1998 due to hepatotoxicity.[47]
• Xibrom® (0.09% BID): The first ophthalmic formulation, approved in March 2005. It was later discontinued in February 2011 after being superseded by a once-daily version.[1] The FDA subsequently determined that Xibrom® was not withdrawn for reasons of safety or effectiveness, which cleared a pathway for future generic applications referencing it.[69]
• Bromday® (0.09% QD): Approved in October 2010 as the first once-daily ophthalmic NSAID, it has since been discontinued.[18]
• Prolensa® (0.07% QD): A lower-concentration, once-daily formulation approved in 2013.[27]
• BromSite® (0.075% BID): A twice-daily formulation in the DuraSite® delivery vehicle, approved in April 2016.[27]
• Generics: Beginning around 2014, the FDA has approved multiple Abbreviated New Drug Applications (ANDAs) for generic versions of the 0.09%, 0.07%, and 0.075% formulations, significantly increasing market competition.[72]
• Europe (EMA): Bromfenac 0.09% was approved in 2011 under the brand name Yellox® for the treatment of postoperative ocular inflammation following cataract extraction.[2]
• Japan (PMDA): Japan was the first country to approve ophthalmic Bromfenac. It was approved as Bronuck® 0.1% in 2000, with broader indications that include blepharitis, conjunctivitis, and scleritis, in addition to postoperative inflammation.[9] Several other local brands, such as "Bromfenac Na Ophthalmic Solution 0.1% 'NITTO'" and "'NITTEN'", are also available.[75]
• Canada (Health Canada): Prolensa® (0.07% solution) received a Notice of Compliance and was authorized for sale in 2015 for the treatment of postoperative inflammation and reduction of ocular pain after cataract surgery.[77]
• Australia (TGA): A direct search of the Australian Register of Therapeutic Goods (ARTG) and related public documents did not yield a specific approval for a Bromfenac-containing product, although the regulatory framework for such approvals is well-defined.[78]

9.2 Evolution of Ophthalmic Formulations and Brand Proliferation

The commercial history of ophthalmic Bromfenac in the United States is a clear illustration of pharmaceutical lifecycle management, a strategy used by manufacturers to extend the commercial viability of a drug. The progression from one formulation to the next was not random but a series of deliberate steps to enhance clinical value and defend market share against generic erosion.

Initially, ISTA Pharmaceuticals launched the twice-daily Xibrom® in 2005.[69] As the product matured and faced the prospect of generic competition, the company leveraged the drug's favorable pharmacokinetic data, which showed a duration of action exceeding 12 hours, to develop and test a once-daily formulation.[12] This led to the approval of Bromday® in 2010, which, as the first once-daily ophthalmic NSAID, offered a significant convenience and adherence advantage. This new dosing regimen was granted a three-year period of market exclusivity, effectively delaying generic entry.[70]

This was followed by further refinements: Prolensa® (0.07%) was introduced in 2013 with a lower concentration and a more physiologic pH, and BromSite® (0.075%) was launched in 2016, shifting the focus of innovation from the drug itself to its delivery vehicle, DuraSite®, to enhance bioavailability and secure a unique indication for pain prevention.[9] Each step represented a strategic effort to create a "new and improved" version, obtain new intellectual property or exclusivity, and maintain brand presence. The eventual arrival of generic versions for each of these formulations marks the final stage of this product lifecycle, introducing intense price competition.[72]

10.0 Conclusion and Expert Insights

Bromfenac (DB00963) has firmly established itself as a potent and effective nonsteroidal anti-inflammatory drug within the specialized field of ophthalmology. Its clinical success is fundamentally built on a sophisticated understanding of its structure-activity relationship. The strategic bromination of the amfenac molecule creates a synergistic effect, simultaneously enhancing its intrinsic inhibitory potency against the COX-2 enzyme and increasing its lipophilicity for superior penetration into ocular tissues. This elegant molecular engineering is the primary driver of its clinical efficacy.

The resulting pharmacokinetic profile, characterized by rapid absorption, high concentration in target tissues, and a prolonged duration of action, allows for convenient once or twice-daily dosing. This represents a significant practical advantage over older ophthalmic NSAIDs that require more frequent administration, thereby improving the likelihood of patient adherence during the critical postoperative period. The primary clinical trade-off for prescribers and patients is balancing the potency and convenience of Bromfenac against its substantially higher cost compared to older, generic alternatives like ketorolac and diclofenac.

The safety profile of ophthalmic Bromfenac is well-characterized and favorable for its intended short-term use. The most common adverse events are mild and localized, while the most serious risk—rare but potentially sight-threatening corneal events—necessitates careful patient selection and diligent monitoring, especially in those with pre-existing risk factors. The history of Bromfenac is perhaps most notable for the stark contrast between the safety of the ophthalmic solution and the severe hepatotoxicity of its withdrawn oral predecessor, Duract®. This dichotomy serves as a critical lesson in pharmacology, powerfully demonstrating how the route of administration and resulting pharmacokinetic profile can completely redefine a drug's risk-benefit equation.

In conclusion, Bromfenac holds an important and justified place in the modern ophthalmologist's armamentarium for managing pain and inflammation after cataract surgery. The evolution of its various formulations provides a compelling case study in pharmaceutical innovation, strategic lifecycle management, and the ongoing quest to optimize drug delivery for maximum therapeutic benefit.

Works cited

1. Bromfenac - Wikipedia, accessed August 12, 2025, https://en.wikipedia.org/wiki/Bromfenac
2. Bromfenac | C15H12BrNO3 | CID 60726 - PubChem, accessed August 12, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Bromfenac
3. Bromfenac (ophthalmic route) - Side effects & dosage - Mayo Clinic, accessed August 12, 2025, https://www.mayoclinic.org/drugs-supplements/bromfenac-ophthalmic-route/description/drg-20062377
4. FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Recommended Dosing 2.2 Use with Other Topi, accessed August 12, 2025, https://pi.bausch.com/globalassets/pdf/packageinserts/pharma/rx-generics/bromfenac-ophthalmic-solution-pi.pdf
5. BROMFENAC - Inxight Drugs, accessed August 12, 2025, https://drugs.ncats.io/drug/bromfenac
6. XIBROM™ (bromfenac ophthalmic solution) 0.09% DESCRIPTION CLINICAL PHARMACOLOGY - accessdata.fda.gov, accessed August 12, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021664s010lbl.pdf
7. go.drugbank.com, accessed August 12, 2025, https://go.drugbank.com/drugs/DB00963#:~:text=Bromfenac%20ophthalmic%20solution%20is%20a,inhibiting%20cyclooxygenase%201%20and%202.
8. Update on twice-daily bromfenac sodium sesquihydrate to treat postoperative ocular inflammation following cataract extraction - PubMed Central, accessed August 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3346189/
9. Bromfenac ophthalmic solution for the treatment of postoperative ocular pain and inflammation: safety, efficacy, and patient adherence - PubMed Central, accessed August 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4077855/
10. Differentiating Among the Nonsteroidal Antiinflammatory Drugs, accessed August 12, 2025, https://crstoday.com/wp-content/uploads/sites/4/2017/02/crst0217_SunPharmaCME_Supplement.pdf
11. Comparing NSAIDs - Retinal Physician, accessed August 12, 2025, https://www.retinalphysician.com/issues/2006/september/comparing-nsaids/
12. Ocular Pharmacokinetics of a Single Dose of Bromfenac Sodium Ophthalmic Solution 0.1% in Human Aqueous Humor | Request PDF - ResearchGate, accessed August 12, 2025, https://www.researchgate.net/publication/23562421_Ocular_Pharmacokinetics_of_a_Single_Dose_of_Bromfenac_Sodium_Ophthalmic_Solution_01_in_Human_Aqueous_Humor
13. bromfenac sodium ophthalmic solution, 0.09%. - accessdata.fda.gov, accessed August 12, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021664Orig1s013.pdf
14. Reference ID: 3914891 This label may not be the latest approved by FDA. For current labeling information, please visit https://, accessed August 12, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206911s000lbl.pdf
15. BROMFENAC OPHTHALMIC SOLUTION, 0.09% - Lupin, accessed August 12, 2025, https://www.lupin.com/US/wp-content/uploads/2024/03/pi-bromfenac-ophth-sol-0.09-eq-bromday-8.2023.pdf
16. Bromfenac: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 12, 2025, https://go.drugbank.com/drugs/DB00963
17. Bromfenac (Duract®) - withdrawn from the market: severe liver failure - World Health Organization (WHO), accessed August 12, 2025, https://cdn.who.int/media/docs/default-source/pvg/drug-alerts/da071---drug_alert71bromfenac_withdrawn.pdf?sfvrsn=6fedbfdb_4
18. Update on twice-daily bromfenac sodium sesquihydrate to treat postoperative ocular inflammation following cataract extraction - Dove Medical Press, accessed August 12, 2025, https://www.dovepress.com/getfile.php?fileID=12603
19. Bromfenac - brand name list from Drugs.com, accessed August 12, 2025, https://www.drugs.com/ingredient/bromfenac.html
20. Bromfenac - Drugs and Lactation Database (LactMed®) - NCBI Bookshelf, accessed August 12, 2025, https://www.ncbi.nlm.nih.gov/books/NBK500957/
21. Bromfenac Free Base | CAS# 91714-94-2 (free base) | nonsteroidal anti-inflammatory, accessed August 12, 2025, https://www.medkoo.com/products/46244
22. Bromfenac, accessed August 12, 2025, https://www.drugfuture.com/chemdata/bromfenac.html
23. Bromfenac Monograph for Professionals - Drugs.com, accessed August 12, 2025, https://www.drugs.com/monograph/bromfenac.html
24. Bromfenac sodium | 91714-94-2 - ChemicalBook, accessed August 12, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB8117032.htm
25. Clinical pharmacokinetics and pharmacodynamics of bromfenac - PubMed, accessed August 12, 2025, https://pubmed.ncbi.nlm.nih.gov/10427465/
26. FULL PRESCRIBING INFORMATION 4 - accessdata.fda.gov, accessed August 12, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021664s013lbl.pdf
27. Use of topical bromfenac for treating ocular pain and inflammation beyond cataract surgery: a review of published studies - PubMed Central, accessed August 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6682171/
28. Dosage and Administration - BromSite, accessed August 12, 2025, https://www.bromsite.com/dosage-and-administration
29. In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits, accessed August 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5997598/
30. Pharmacology, clinical efficacy and safety of bromfenac ophthalmic solution | Request PDF, accessed August 12, 2025, https://www.researchgate.net/publication/233504642_Pharmacology_clinical_efficacy_and_safety_of_bromfenac_ophthalmic_solution
31. What is the mechanism of Bromfenac Sodium? - Patsnap Synapse, accessed August 12, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-bromfenac-sodium
32. BROMFENAC SODIUM - Inxight Drugs, accessed August 12, 2025, https://drugs.ncats.io/drug/8ECV571Y37
33. Bromfenac Eye Solution - Cleveland Clinic, accessed August 12, 2025, https://my.clevelandclinic.org/health/drugs/19513-bromfenac-eye-solution
34. Bromfenac Ophthalmic: MedlinePlus Drug Information, accessed August 12, 2025, https://medlineplus.gov/druginfo/meds/a611018.html
35. Nepafenac vs bromfenac: A comparative study to determine their role in maintaining mydriasis during cataract surgery - IJCEO, accessed August 12, 2025, https://www.ijceo.org/html-article/13503
36. 206911Orig1s000 - accessdata.fda.gov, accessed August 12, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/206911Orig1s000PharmR.pdf
37. BromSite, Prolensa (bromfenac ophthalmic) dosing, indications, interactions, adverse effects, and more - Medscape Reference, accessed August 12, 2025, https://reference.medscape.com/drug/bromsite-prolensa-bromfenac-ophthalmic-343667
38. Using Unavailable and Off-label Meds: - Review of Ophthalmology, accessed August 12, 2025, https://www.reviewofophthalmology.com/CMSDocuments/2017/09/rp0917i.pdf
39. Bromfenac Ophthalmic Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed August 12, 2025, https://www.drugs.com/dosage/bromfenac-ophthalmic.html
40. Label: BROMFENAC solution/ drops - DailyMed, accessed August 12, 2025, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b2621e7-a69e-4286-a7e7-0fc31a91fe29
41. Once daily dosing of bromfenac ophthalmic solution 0.09% for postoperative ocular inflammation and pain - PubMed, accessed August 12, 2025, https://pubmed.ncbi.nlm.nih.gov/21751945/
42. Topical bromfenac for prevention and treatment of cystoid macular edema following cataract surgery: a review - PubMed Central, accessed August 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5087782/
43. Topical bromfenac for prevention and treatment of cystoid macular edema following cataract surgery: a review - Dove Medical Press, accessed August 12, 2025, https://www.dovepress.com/topical-bromfenac-for-prevention-and-treatment-of-cystoid-macular-edem-peer-reviewed-fulltext-article-OPTH
44. Bromfenac as a Second Line Therapy for the Management of Post-Operative Cystoid Macular Oedema - Herald Scholarly Open Access, accessed August 12, 2025, https://www.heraldopenaccess.us/openaccess/bromfenac-as-a-second-line-therapy-for-the-management-of-post-operative-cystoid-macular-oedema
45. NDA 206911/S-008 Page 3 - accessdata.fda.gov, accessed August 12, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206911Orig1s008lbl.pdf
46. Bromfenac: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD, accessed August 12, 2025, https://www.webmd.com/drugs/2/drug-163935/prolensa-ophthalmic-eye/details
47. CPY Document - FDA, accessed August 12, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021664s000_PharmR.pdf
48. bromfenac - New Drug Approvals, accessed August 12, 2025, https://newdrugapprovals.org/tag/bromfenac/
49. Bromfenac (Duract)- Associated Hepatic Failure Requiring Liver Transplantation, accessed August 12, 2025, https://www.researchgate.net/publication/12853392_Bromfenac_Duract-_Associated_Hepatic_Failure_Requiring_Liver_Transplantation
50. NSAID and CCB both withdrawn within days | 1998-08-01… | Clinician.com, accessed August 12, 2025, https://www.clinician.com/articles/33580-nsaid-and-ccb-both-withdrawn-within-days
51. (PDF) Severe toxicity associated with bromfenac sodium, accessed August 12, 2025, https://www.researchgate.net/publication/13063877_Severe_toxicity_associated_with_bromfenac_sodium
52. Severe hepatotoxicity associated with bromfenac sodium - PubMed, accessed August 12, 2025, https://pubmed.ncbi.nlm.nih.gov/10235225/
53. A systematic review of NSAIDs withdrawn from the market due to ..., accessed August 12, 2025, https://www.ncbi.nlm.nih.gov/books/NBK73150/
54. 022406Orig1s000 - accessdata.fda.gov, accessed August 12, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022406Orig1s000RiskR.pdf
55. Bromfenac Interactions Checker - Drugs.com, accessed August 12, 2025, https://www.drugs.com/drug-interactions/bromfenac.html
56. Topical bromfenac 0.09% vs. ketorolac 0.4% for the control of pain, photophobia, and discomfort following PRK - PubMed, accessed August 12, 2025, https://pubmed.ncbi.nlm.nih.gov/19241773/
57. Bromfenac and ketorolac equally safe and effective for post-PRK treatment, accessed August 12, 2025, https://www.ophthalmologytimes.com/view/bromfenac-and-ketorolac-equally-safe-and-effective-post-prk-treatment
58. Ketorolac eye drops (Acular, Acuvail): Uses, Side Effects, Dosage & More - GoodRx, accessed August 12, 2025, https://www.goodrx.com/acular/what-is
59. Bromfenac Ophthalmic vs Ketorolac Ophthalmic Comparison - Drugs.com, accessed August 12, 2025, https://www.drugs.com/compare/bromfenac-ophthalmic-vs-ketorolac-ophthalmic
60. The importance of preoperative topical non-steroidal antiinflammatory agents in cataract surgery- an open label prospective randomised comparative study - Tropical Journal of Ophthalmology and Otolaryngology - Medresearch, accessed August 12, 2025, https://opthalmology.medresearch.in/index.php/jooo/article/download/89/139/
61. Nepafenac vs bromfenac: A comparative study to determine their role in maintaining mydriasis during cataract surgery, accessed August 12, 2025, https://ijceo.org/article-details/13503
62. (PDF) Comparative study of the efficacy and safety of bromfenac, nepafenac and diclofenac sodium for the prevention of cystoid macular edema after phacoemulsification - ResearchGate, accessed August 12, 2025, https://www.researchgate.net/publication/326655504_Comparative_study_of_the_efficacy_and_safety_of_bromfenac_nepafenac_and_diclofenac_sodium_for_the_prevention_of_cystoid_macular_edema_after_phacoemulsification
63. Anesthesia and Ocular Tolerability of Topical Non–Steroidal Anti–Inflammatory Drugs: A Direct Comparison Between Bromfenac and Nepafenac | IOVS, accessed August 12, 2025, https://iovs.arvojournals.org/article.aspx?articleid=2394778
64. The Comparative Efficacy and Tolerability of Diclofenac 0.1% and ..., accessed August 12, 2025, https://pubmed.ncbi.nlm.nih.gov/30009640/
65. Ophthalmic NSAIDs Review - Medicaid.nv.gov, accessed August 12, 2025, https://www.medicaid.nv.gov/Downloads/provider/NVRx_DCR_20090326_Ophthalmic_NSAIDs.pdf
66. 5 NSAID Eye Drops: A Full List of Options - GoodRx, accessed August 12, 2025, https://www.goodrx.com/classes/nsaids/nsaid-eye-drops
67. Bromfenac Ophthalmic vs Diclofenac Ophthalmic Comparison - Drugs.com, accessed August 12, 2025, https://www.drugs.com/compare/bromfenac-ophthalmic-vs-diclofenac-ophthalmic
68. Therapeutic Class Overview Ophthalmic Nonsteroidal Anti-Inflammatory Drugs - Medicaid.nv.gov, accessed August 12, 2025, https://www.medicaid.nv.gov/Downloads/provider/Ophthalmic%20Nonsteroidal%20Anti_09222016.pdf
69. Determination That XIBROM (Bromfenac Ophthalmic Solution) 0.09% Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness - Federal Register, accessed August 12, 2025, https://www.federalregister.gov/documents/2011/05/13/2011-11745/determination-that-xibrom-bromfenac-ophthalmic-solution-009-was-not-withdrawn-from-sale-for-reasons
70. Bromday (bromfenac) FDA Approval History - Drugs.com, accessed August 12, 2025, https://www.drugs.com/history/bromday.html
71. BromSite (bromfenac) FDA Approval History - Drugs.com, accessed August 12, 2025, https://www.drugs.com/history/bromsite.html
72. FDA approves generic once-daily bromfenac - American Academy of Ophthalmology, accessed August 12, 2025, https://www.aao.org/education/headline/fda-approves-generic-oncedaily-bromfenac
73. FDA approves Lupin's BromSite generic equivalent for postop inflammation and pain, accessed August 12, 2025, https://glance.eyesoneyecare.com/stories/2024-02-07/fda-approves-lupin-s-bromsite-generic-equivalent-for-postop-inflammation-and-pain/
74. Lupin Receives Approval from U.S. FDA for Bromfenac Ophthalmic Solution, 0.075%, accessed August 12, 2025, https://www.lupin.com/lupin-receives-approval-from-u-s-fda-for-bromfenac-ophthalmic-solution-0-075/
75. Bromfenac Na Ophthalmic Solution 0.1%"NITTO" | Kusuri-no-Shiori(Drug Information Sheet), accessed August 12, 2025, https://www.rad-ar.or.jp/siori/english/search/result?n=42458
76. Bromfenac Sodium Ophthalmic Solution 0.1% "NITTEN" | Kusuri-no-Shiori(Drug Information Sheet), accessed August 12, 2025, https://www.rad-ar.or.jp/siori/english/search/result?n=45087
77. Summary Basis of Decision for Prolensa - Drug and Health Products Portal, accessed August 12, 2025, https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SBD00265
78. Australian Register of Therapeutic Goods (ARTG), accessed August 12, 2025, https://www.tga.gov.au/products/australian-register-therapeutic-goods-artg
79. What does TGA approval of medicines mean? - Australian Prescriber, accessed August 12, 2025, https://australianprescriber.tg.org.au/articles/what-does-tga-approval-of-medicines-mean.html
80. TGA Archives - Insight, accessed August 12, 2025, https://www.insightnews.com.au/ophthalmc-insights/product-approvals/tga-product-approvals/
81. ISTA asks FDA to prohibit generic BID bromfenac - Ophthalmology Times, accessed August 12, 2025, https://www.ophthalmologytimes.com/view/ista-asks-fda-prohibit-generic-bid-bromfenac